Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706121 | 0.78 | PDE2A (0.62) | PDE2AAKT1AKT2SLC6A2HTR2A | |
| SCHEMBL7370103 | 0.78 | — | — | |
| SCHEMBL21735 | 0.77 | TSHR (0.48) | — | |
| SCHEMBL1121775 | 0.77 | ESR1 (0.46) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27666552 | 0.77 | — | — | |
| Water SCHEMBL28104416 | 0.77 | TSHR (0.48) | — | |
| SCHEMBL28195180 | 0.77 | KCNN4 (0.30) | — | |
| SCHEMBL1176245 | 0.74 | TSHR (0.50) | SLC6A2SLC6A4SLC6A3 | |
| Water SCHEMBL4609376 | 0.74 | KCNN4 (0.55) | PDE2AAKT1AKT2SLC6A2 | |
| SCHEMBL27344926 | 0.74 | TSHR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526220-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2019-08-21 | — | — | EP | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| WO-2018071836-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-04-19 | — | — | WO | claimed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | claimed |
| US-20160264570-A1 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | LOYOLA UNIVERSITY OF CHICAGO | 2016-09-15 | — | — | US | claimed |
| WO-2015073804-A2 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-05-21 | — | — | WO | claimed |
| US-8785448-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-22 | — | — | US | claimed |
| US-20130344031-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-26 | — | — | US | claimed |
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2013-05-09 | — | — | US | claimed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | claimed |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-04 | — | — | US | claimed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | claimed |
| US-5756466-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS, INC. (US) | 1998-05-26 | — | — | US | claimed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | claimed |
| US-5616711-A | REACTING BUTENE DERIVATIVE TO AN AMIDE DERIVATIVE; USEFUL AS INTERMEDIATES FOR PRODUCING ANTIULCER DRUGS | FUJIREBIO INC. (JP) | 1997-04-01 | — | — | US | claimed |
| EP-0582304-A2 | Methods of producing amino butene derivatives | FUJIREBIO Inc. (JP) | 1994-02-09 | — | — | EP | claimed |
| EP-0049173-B1 | PYRIMIDONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL DERIVATIVES CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-07-03 | — | — | EP | claimed |
| US-4385058-A | HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-05-24 | — | — | US | claimed |
| EP-0049173-A2 | Pyrimidone derivatives, processes for their preparation and pharmaceutical derivatives containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1982-04-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | PDE2A 1449/4885AKT1 1669/4885AKT2 2821/4885 |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | PDE2A 569/4885AKT1 1384/4885AKT2 1682/4885 |
| US-20160264570-A1 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | PLK1, TUBA1C, PPT1 | PDE2A 3128/4885AKT1 1224/4885AKT2 1361/4885 |
| US-20130344031-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | CCNI, CDK1, CDK2 | PDE2A 2468/4885AKT1 186/4885AKT2 238/4885 |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, APAF1, IL1B | PDE2A 1835/4885AKT1 4182/4885AKT2 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.